IP Library › Granted Patent US 12,290,542
Granted Patent B2
US 12,290,542 · App. 18/597,236 · Granted May 6, 2025

Compositions comprising cannabis and mushroom extracts, and uses thereof

Inventors: Parker Berling (San Francisco, CA); Tony M. Verzura (San Francisco, CA); Kevin Hall (San Francisco, CA)
Assignee: Cookies Creative Consulting & Promotions, Inc.
A61K36/07A61K31/015A61K31/56A61K31/658A61K36/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,542
App. No.
18/597,236
Granted
May 6, 2025
Kind
B2
Abstract

The present disclosure provides for compositions combining Cannabinoid Fractions and Mushroom Extract Fractions for recreational and medicinal uses. The disclosed compositions are useful for treating symptoms of anxiety, stress, pain, and promoting sleep. The pharmaceutical compositions comprise particular cannabinoid ratios and terpene profiles.

Claims (23)

1. A capsule comprising:

i. a Cannabinoid Fraction comprising purified cannabidiol (CBD) and purified cannabinol (CBN);

ii. a Mushroom Extract Fraction comprising Trametes versicolor, Ganoderma lingzhi, Grifola frondosa, Lentinula edodes , and Inonotus obliquus; and

iii. a Terpene Fraction.

2. The capsule of claim 1 , wherein the Terpene Fraction comprises:

at least two terpenes selected from the group consisting of: alpha pinene, limonene, beta-pinene, alpha phellandrene, terpinolene, nerolidol, and nerol.

3. The capsule of claim 1 , wherein the Terpene Fraction comprises: alpha pinene, limonene, beta-pinene, alpha phellandrene, terpinolene, nerolidol, and nerol.

4. The capsule of claim 1 , further comprising valerian root.

5. The capsule of claim 1 , comprising from about 10 mg to about 20 mg of CBD.

6. The capsule of claim 1 , comprising about 15 mg of CBD.

7. The capsule of claim 1 , comprising from about 5 mg to about 15 mg of CBN.

8. The capsule of claim 1 , comprising about 10 mg of CBN.

9. The capsule of claim 1 , wherein the CBN and CBD are present in a ratio of about 2:3 by weight, respectively.

10. The capsule of claim 1 , comprising from about 50 to about 70 mg of each of Trametes versicolor, Ganoderma lingzhi, Grifola frondosa, Lentinula edodes , and Inonotus obliquus.

11. The capsule of claim 1 , comprising about 60 mg of Trametes versicolor.

12. The capsule of claim 1 , comprising about 60 mg of Ganoderma lingzhi.

13. The capsule of claim 1 , comprising about 60 mg of Grifola frondosa.

14. The capsule of claim 1 , comprising about 60 mg of Lentinula edodes.

15. The capsule of claim 1 , comprising about 60 mg of Inonotus obliquus.

16. The capsule of claim 1 , wherein the Trametes versicolor, Ganoderma lingzhi, Grifola frondosa, Lentinula edodes , and Inonotus obliquus are present in a ratio of about 1:1 by weight, respectively.

17. The capsule of claim 1 , wherein the Terpene Fraction comprises alpha pinene, limonene, beta-pinene, alpha phellandrene, terpinolene, nerolidol, and nerol; wherein CBN and CBD are present in a ratio of about 2:3 by weight, respectively and wherein Trametes versicolor, Ganoderma lingzhi,, Grifola frondosa, Lentinula edodes , and Inonotus obliquus are present in a ratio of about 1:1:1:1:1, by weight, respectively.

18. The capsule of claim 1 , further comprising hypromellose, microcrystalline cellulose, inositol, medium chain triglyceride (MCT) oil, and tapioca starch.

19. The capsule of claim 17 , further comprising hypromellose, microcrystalline cellulose, inositol, medium chain triglyceride (MCT) oil, and tapioca starch.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: BERLING, PARKER; VERZURA, TONY M.; HALL, KEVIN
To: COOKIES CREATIVE CONSULTING & PROMOTIONS, INC.
Reel/Frame 066701/0504 →
Continuity (4)
Continuation 18343563 · Jun 28, 2023
Continuation PCTUS2021065708 · Dec 30, 2021
Provisional Application 63132878 · Dec 31, 2020
Related Publication 20240252569A1 · Aug 1, 2024
References Cited (47)
US 3033690A · Tarvin et al. · 1962 [cited by applicant]
US 7258862B2 · Mahajna et al. · 2007 [cited by applicant]
US 7700368B2 · Flockhart et al. · 2010 [cited by applicant]
US 8481085B2 · Musty et al. · 2013 [cited by applicant]
US 9359625B2 · Winnicki et al. · 2016 [cited by applicant]
US 9744200B1 · Tucker et al. · 2017 [cited by applicant]
US 10159908B2 · Thomas · 2018 [cited by applicant]
US 10555914B1 · Metcalf · 2020 [cited by applicant]
US 20080031977A1 · Musty et al. · 2008 [cited by applicant]
US 20160000754A1 · Stamets · 2016 [cited by examiner]
US 20180078874A1 · Thomas · 2018 [cited by applicant]
US 20180193403A1 · George et al. · 2018 [cited by applicant]
US 20180200224A1 · Stamets · 2018 [cited by applicant]
US 20190151771A1 · Thomas · 2019 [cited by applicant]
US 20200048214A1 · Thomas et al. · 2020 [cited by applicant]
US 20200048215A1 · Thomas et al. · 2020 [cited by applicant]
US 20200080021A1 · Thomas · 2020 [cited by applicant]
US 20200246404A1 · Yucel et al. · 2020 [cited by applicant]
US 20200330378A1 · Friedman · 2020 [cited by applicant]
US 20200352206A1 · Wagner-Salvini · 2020 [cited by applicant]
US 20230338447A1 · Berling et al. · 2023 [cited by applicant]
WO WO2015065544A1 · 2015 [cited by applicant]
WO WO2016200438A1 · 2016 [cited by applicant]
WO WO2020136593A1 · 2020 [cited by applicant]
WO WO2020188577A1 · 2020 [cited by applicant]
Bartlett et al., “Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine,” AAPS PharmSciTech vol. 13(4), pp. 1110-1115 (2012). [cited by applicant]
Caglarirmak et al., “The nutrients of exotic mushrooms ( [cited by applicant]
Eubanks et al.,“A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology,” Molecular Pharmaceutics 3(6): 773-777 (2006). [cited by applicant]
Gery et al., “Chaga ( [cited by applicant]
Herring et al., “Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes,” Journal of Pharmacology and Experimental Therapeutic… [cited by applicant]
Hoaken, “Drugs of abuse and the elicitation of human aggressive behavior,” Addictive Behaviors 28: 1533-1554 (2003). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/065708 dated Mar. 17, 2022, 21 pages. [cited by applicant]
Li et al., “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines,” Behavioral Neurology Article ID 5802634, 10 pages (2018). [cited by applicant]
Marks et al., “Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa,” Journal of Experimental Botany 60 (13): 3715-3726 (Jul. 2009). [cited by applicant]
McAllister et al., “Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells,” Mol. Cancer Ther. 6 (11): 2921-7 (Nov. 2007). [cited by applicant]
Mechoulam et al., “Cannabidiol—Recent Advances,” Chemistry & Biodiversity 4(8):1678-1692 (2007). [cited by applicant]
Nicholson et al., “Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults,” J Clin Psychopharmacol. Jun. 2004;24(3):305-13 (Jun. 2004). [cited by applicant]
Pickens, “Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content,” Br J Pharmacol. Apr. 1981;72(4):649-56 (1981). [cited by applicant]
Pollastro et al., “Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids,” J Nat Prod;81(3):630-633 (Mar. 23, 2018). Epub Dec. 14, 2017. [cited by applicant]
Qu et al., “Anticancer effect of triterpenes from Ganoderma lucidum in human prostate cancer cells,” Oncol Lett 14(6): 7467-7472 (Dec. 2017). Published online Oct. 9, 2017. [cited by applicant]
Russo et al., “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” Br J Pharmacol 163(7):1344-64 (Aug. 2011). [cited by applicant]
Salehi et al., “Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature,” Biomolecules 9(11):738 (2019). [cited by applicant]
Smiderle et al., “Anti-Inflammatory Properties of the Medicinal Mushroom Cordyceps militaris Might Be Related to Its Linear (1R3)-b-D-Glucan,” PLoS One 9(10): e110266, pp. 1-11 (2014). [cited by applicant]
Taura et al., “Purification and Characterization of Cannabidiolic-acid Synthase from [cited by applicant]
Tuli et al., “Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin,” 3 Biotech 4(1):1-12 (2014). [cited by applicant]
Valdeolivas et al., “Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice,” Neurotherapeutics 12(1):185-99 (Jan. 2015). [cited by applicant]
Extended European Search Report for European Application No. 21916507.3 mailed Nov. 28, 2024, 7 pages. [cited by applicant]